Durect shares rocked by midstage psoriasis flop, shifts focus to liver disease

Durect’s stock nose-dived more than 30% yesterday on the news that its phase 2 plaque psoriasis hope failed to beat out a sham treatment.

The drug, known as DUR-928 and used here as a topical treatment, was pitted against placebo for around a month in just under two dozen patients.